
To investigate to what extent multiple risk marker improvements confer lower risk of cardiovascular and kidney complications in a contemporary type 2 diabetes population. Post‐hoc analysis of the LEADER (n = 8638; median follow‐up 3.8 years) and SUSTAIN 6 (n = 3040; median follow‐up 2.1 years) cardiovascular outcome trials. Participants: those with baseline and year‐1 assessment of at least one of the parameters of interest; we pooled the liraglutide−/semaglutide‐ and placebo‐treated groups and categorized them by number of risk markers with clinically relevant improvements after 1 year of study participation. We investigated risk of major adverse cardiovascular events (MACE), expanded MACE, cardiovascular death and nephropathy...
Like
Save
Share